Vaccinex’s mission is to deliver innovative therapies that improve the lives of patients and provide treatment solutions for critical unmet needs. Through deep understanding of science and pathology of disease, we are pioneering a differentiated approach to treating neurologic diseases and cancer with novel antibody therapeutics. We are grateful to the patients, families, and the clinical staff that participate in our clinical trials. Each individual’s participation contributes to the potential to realize benefit for patients today and to advance our understanding of disease for the next generation.


A clinical trial is a controlled study to evaluate the safety and efficacy (how well it works) of an experimental drug treatment. These studies are required before a drug can be approved by a regulatory agency such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA). Patients interested in participating in a clinical trial must meet certain eligibility criteria and be willing to follow directions of the physician in charge of the study.


Clinical Trials with pepinemab


SIGNAL-AD Alzheimer’s Disease
Evaluating the Safety and Efficacy of our drug Pepinemab in Patients with Alzheimer’s Disease.
Phase 1b/2

Condition(s) Alzheimer Disease (AD)


Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation

Click for more information about our Neurology Programs


Keynote B84 Head and Neck Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 1b/2

Condition(s) Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)


Merck Sharp & Dohme Corp.

Click for more information about our Cancer Programs